Fate Therapeutics and Stemgent Team Up to Offer Stem Cell Advances to the Research Market

Fate Therapeutics and Stemgent have jointly created the Catalyst program to make new developments in iPS cells available to companies and academic labs. This could significantly aid companies and researchers investigating the use of iPS cells for therapies for ALS and other diseases.

Click here to read this article.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail